JP2013527138A - 神経変性または神経血管性疾患の治療のための新規の医薬組成物 - Google Patents

神経変性または神経血管性疾患の治療のための新規の医薬組成物 Download PDF

Info

Publication number
JP2013527138A
JP2013527138A JP2012556457A JP2012556457A JP2013527138A JP 2013527138 A JP2013527138 A JP 2013527138A JP 2012556457 A JP2012556457 A JP 2012556457A JP 2012556457 A JP2012556457 A JP 2012556457A JP 2013527138 A JP2013527138 A JP 2013527138A
Authority
JP
Japan
Prior art keywords
disease
pharmaceutical composition
dementia
neurodegenerative
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012556457A
Other languages
English (en)
Japanese (ja)
Inventor
ボーシェ、オリビエ
アンウェイレ、セドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite dAngers
Centre Hospitalier Universitaire dAngers
Original Assignee
Universite dAngers
Centre Hospitalier Universitaire dAngers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite dAngers, Centre Hospitalier Universitaire dAngers filed Critical Universite dAngers
Publication of JP2013527138A publication Critical patent/JP2013527138A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012556457A 2010-03-05 2011-03-04 神経変性または神経血管性疾患の治療のための新規の医薬組成物 Ceased JP2013527138A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31078910P 2010-03-05 2010-03-05
EP10305227A EP2363119A1 (fr) 2010-03-05 2010-03-05 Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
US61/310,789 2010-03-05
EP10305227.0 2010-03-05
PCT/EP2011/053274 WO2011107582A1 (en) 2010-03-05 2011-03-04 Novel pharmaceutical composition for the treatment of neurodegenerative or neurovascular diseases

Publications (1)

Publication Number Publication Date
JP2013527138A true JP2013527138A (ja) 2013-06-27

Family

ID=42332371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012556457A Ceased JP2013527138A (ja) 2010-03-05 2011-03-04 神経変性または神経血管性疾患の治療のための新規の医薬組成物

Country Status (6)

Country Link
US (1) US20130012483A1 (zh)
EP (2) EP2363119A1 (zh)
JP (1) JP2013527138A (zh)
CN (1) CN102821760B (zh)
CA (1) CA2790654A1 (zh)
WO (1) WO2011107582A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819303T3 (es) * 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
WO2014063105A1 (en) * 2012-10-19 2014-04-24 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
KR20150134402A (ko) * 2013-03-27 2015-12-01 디에스엠 아이피 어셋츠 비.브이. 집행 기능 향상을 위한 25-하이드록시비타민 d3의 용도
CN106668865B (zh) * 2017-01-23 2019-07-23 牡丹江医学院 用于治疗脑缺血的药物组合物、制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
JPH09507830A (ja) * 1993-07-15 1997-08-12 ザ ユニバーシティ オブ ケンタッキー リサーチ ファンデーション ニューロン喪失からの保護方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
AU2002320251A1 (en) * 2001-07-05 2003-01-21 Vital Basics, Inc. Compositions for improving mental performance
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8178132B2 (en) * 2007-03-22 2012-05-15 Magceutics, Inc. Magnesium-containing food compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
JPH09507830A (ja) * 1993-07-15 1997-08-12 ザ ユニバーシティ オブ ケンタッキー リサーチ ファンデーション ニューロン喪失からの保護方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015001835; Ｌｉｆｅ　Ｓｃｉｅｎｃｅｓ Ｖｏｌ．６６，　Ｎｏ．１２, 2000, ｐ．１０７９-１０８３ *
JPN6015001836; Ｔｒｅｎｄｓ　ｉｎ　Ｅｎｄｏｃｒｉｎｏｌｏｇｙ　＆　Ｍｅｔａｂｏｌｉｓｍ Ｖｏｌ．１３，　Ｎｏ．３, 2002, ｐ．１００-１０５ *

Also Published As

Publication number Publication date
CN102821760B (zh) 2014-11-05
EP2363119A1 (fr) 2011-09-07
EP2542231A1 (en) 2013-01-09
CN102821760A (zh) 2012-12-12
WO2011107582A1 (en) 2011-09-09
CA2790654A1 (en) 2011-09-09
US20130012483A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
US11116773B2 (en) Method of treating dementia
KR20030025902A (ko) 덱스트로메토르판 및 옥시다제 억제제의 환자의 마약 및항진정제의 중단을 위한 용도
KR20080004581A (ko) 불안 관련 장애의 치료 방법
US11690849B2 (en) Method of treating dementia
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
CA3213864A1 (en) Dosing regimen of tradipitant
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
CN107614061A (zh) 用于治疗与疼痛有关的偏头痛和病症方法和组合物
JP2013527138A (ja) 神経変性または神経血管性疾患の治療のための新規の医薬組成物
US20120009278A1 (en) Composition To Retard the Onset of Symptoms of Alzheimer's Disease
US9415064B2 (en) Prevention or treatment of painful polyneuropathies by administration of an aluminosilicate
EP3323416B1 (en) Pharmaceutical composition for treating premature ejaculation
WO2020115751A1 (en) Cannabis-based compositions for the treatment of alzheimer's disease and dementia
EP3463296A1 (en) Pharmaceutical formulations of nitrite uses thereof
DE10318714B4 (de) Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
WO2023227881A1 (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
GB2619119A (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151030

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151111

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151222

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20160426